Accelerating Time to Proof-of-Concept to De-Risk Dermatology Pipelines & Unlock Faster Decision-Making

• Reducing time to proof-of-concept through optimized early study design, enabling faster signal detection, to accelerate go/no-go decisions and reduce R&D spend
• Identifying tools to detect early efficacy signals in large patient cohorts, improving trial efficiency, to minimize costly late-stage failures
• Streamlining development pathways for systemic and early-stage assets, enhancing operational speed, to bring therapies to patients faster

Speakers:

Patti Giblin

Chief Scientific Officer

Ability Biologics